All Posts Tagged With: "TMO"

(LIFE) MedTech Industry Stock Update – May 2013 – Zacks Analyst Interviews

As expected, MedTech mergers and acquisitions (M&A) are heating up in 2013. Finally, the much-hyped takeover battle for Life Technologies Corporation (LIFE) came to an end last month with Thermo Fisher Scientific...

15May2013 | | Comments Off | Continued

(LIFE) Thermo Fisher Scientific Wins Life Technologies Corporation Takeover Battle

Finally, the much hyped takeover battle for Life Technologies Corporation (LIFE) came to an end on Monday with Thermo Fisher Scientific (TMO) emerging as the clear...

27Apr2013 | | Comments Off | Continued

(JNJ) MedTech Industry Stock Outlook – January 2013 – Zacks Analyst Interviews

We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China –...

31Jan2013 | | Comments Off | Continued

(ARE) Alexandria Real Estate Equities Pens New Lease Deals

Pasadena, California-based real estate investment trust (REIT), Alexandria Real Estate Equities, Inc. (ARE), recently entered into long-term agreements with four prestigious companies. The agreements are intended to...

23Oct2012 | | Comments Off | Continued

(SNN) MedTech Industry Stock Outlook – October 2012 – Zacks Analyst Interviews

The global medical devices industry is fairly large, intensely competitive and highly innovative. A regulated industry, MedTech is spread across different segments including cardiology, cardiovascular, neuro, orthopedic and aesthetic devices. The US medical devices industry relies largely on an aging...

4Oct2012 | | Comments Off | Continued

(PKI) PerkinElmer Remains Neutral

We maintain our Neutral rating on PerkinElmer (PKI) based on its second quarter results. Adjusted earnings per share of 53 cents surpassed the Zacks Consensus Estimate of 48 cents. Net income from continuing operations in the reported...

22Aug2012 | | Comments Off | Continued

(JNJ) MedTech Stock Outlook – June 2012 – Industry Outlook

Over the recent past, medical technology (MedTech) players have faced the brunt of exigent economic conditions and a precarious healthcare environment. The performance of the players was thereby hamstrung by several macro issues, including sustained price erosion and procedure volume pressures. The...

16Jun2012 | | Comments Off | Continued

(ARE) Alexandria Real Estate Equities Sees New Lease Agreements

Alexandria Real Estate Equities, Inc. (ARE), a real estate investment trust (REIT), recently entered into long-term agreements with six prestigious life science and technologies companies, to lease a total of 187,000...

10Jun2012 | | Comments Off | Continued

(MDT) MedTech Industry Stock Outlook – March 2012 – Zacks Analyst Interviews

Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The...

19Mar2012 | | Comments Off | Continued

(MDT) MedTech Industry Stock Outlook – March 2012 – Industry Outlook

Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The...

8Mar2012 | | Comments Off | Continued

(STJ) New Year Bets from MedTech

Picking the right stock is never easy, especially in a difficult and volatile market. There are thousands of stocks to choose from and many investors eventually end up boiling the ocean. The U.S. economy continues to be cramped by a spate of headwinds including a still unstable job market,...

6Jan2012 | | 0 comments | Continued

(TMO) Thermo Fisher Scientific Shares Maintained at Neutral

Recently, we reiterated our Neutral recommendation on Thermo Fisher Scientific (TMO) with a target price of $47.00. Thermo Fisher continues to be focused on effectively deploying its cash balance to create value through share...

30Nov2011 | | 0 comments | Continued

(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook

The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure...

18Nov2011 | | 0 comments | Continued

(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook

June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the...

8Sep2011 | | 0 comments | Continued

(BA) Company News for July 28, 2011 – Corporate Summary

•    Boeing (NYSE:BA) reported Q2 EPS of $1.25, beating the Zacks Consensus Estimate of $0.97 per share. Revenues for the quarter rose 6.2% year-over-year to $ 16.5 billion •    Thermo Fisher (NYSE:TMO)...

28Jul2011 | | 0 comments | Continued

(PKI) PerkinElmer Analyst Upgrades Shares to Outperform

We upgrade our rating on PerkinElmer (PKI) to Outperform based on solid results and benefits accruing from extensive reorganization. First-quarter 2011 earnings per share of 34 cents surpassed the Zacks Consensus Estimate of 30 cents....

29Jun2011 | | 0 comments | Continued

(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook

A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected...

22Jun2011 | | 0 comments | Continued

(PKI) PerkinElmer Presents Corporate Social Responsibility Report

A global leader in human and environmental health, PerkinElmer (PKI) recently released its Corporate Social Responsibility (“CSR”) Report for 2010. This report provides information on the company’s achievements against its worldwide...

22Jun2011 | | 0 comments | Continued

(VIVO) FDA OKs Meridian C. Difficile Test

Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH....

13May2011 | | 0 comments | Continued

(AFFX) Affymetrix Analyst Initiates Shares at Neutral

We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus Estimate while profit...

17Apr2011 | | 0 comments | Continued

(DGX) Quest Diagnostics Expedites Celera Acquisition

Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced...

15Apr2011 | | 0 comments | Continued

(AAPL) Company News For December 13, 2010 – Corporate Summary

• Thermo Fisher (NYSE:TMO) said it would purchase Dionex (NASDAQ:DNEX), a manufacturer of chemical analysis equipment, for $118.50 per share, or $2.1 billion • According to this weekend’s...

13Dec2010 | | 0 comments | Continued

(WAT) Waters Corporation Earnings Slightly Below The Street

Waters Corp. (WAT) released its third quarter earnings before the market opened today, reporting earnings from continuing operation of 96 cents, slightly below the Zacks Consensus Estimate of 97 cents.  Earnings in the quarter increased...

3Nov2010 | | 0 comments | Continued

(WAT) Waters Corporation Third Quarter 2010 Earnings Preview

Waters Corp. (WAT) is slated to report its third quarter 2010 earnings on October 26, 2010 before the opening bell. The current Zacks Consensus Estimate for the third quarter is 97 cents per share, representing a year-over-year growth...

25Oct2010 | | 0 comments | Continued

(PKI) PerkinElmer Signs to Aquire Signature Genomic Laboratories

PerkinElmer Inc. (PKI) announced recently that it has agreed to acquire Signature Genomic Laboratories LLC, a diagnostic genetic testing company. The transaction is expected to close in May 2010. As per the filing with the US...

20Apr2010 | | 0 comments | Continued

(TMO) Thermo Fisher Scientific Announces Aquisition of Proxeon

Thermo Fisher Scientific Inc. (TMO) announced that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis. Financial terms of the transaction have not been disclosed. Thermo Fisher plans to integrate...

19Apr2010 | | 0 comments | Continued

(TMO) Thermo Fisher Scientific Analyst Remains Neutral

We have retained our ‘Neutral’ rating on Thermo Fisher Scientific, Inc. (TMO) with a target price of $55 based on a P/E of 16.2 and our fiscal 2010 EPS estimate of $3.39. The company’s results for the fourth quarter and fiscal...

14Apr2010 | | 0 comments | Continued

(TMO) Thermo Fisher Scientific Expands Agreement with Eli Lilly

Thermo Fisher Scientific Inc. (TMO) recently expanded its clinical trial materials supply chain relationship agreement with Eli Lilly and Company (LLY). Per the new...

29Mar2010 | | 0 comments | Continued

(TMO) Thermo Fisher Scientific Acquires Finnzymes

Thermo Fisher Scientific, Inc. (TMO) recently completed the acquisition of Finnzymes. Financial terms of the agreement have not been disclosed. The acquisition is not expected to have any material impact on the company’s financial...

9Mar2010 | | 0 comments | Continued

(TMO) Thermo Fisher Scientific Acquires Ahura

Thermo Fisher Scientific, Inc. (TMO) recently completed the acquisition of Ahura Scientific for $145 million in cash plus the potential for an earn-out payment based on the achievement of certain 2010 financial targets. Thermo...

1Mar2010 | | 0 comments | Continued